Susquehanna International Group’s Grace Therapeutics GRCE Stock Holding History

Susquehanna International Group’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-37,793	Closed	-$113K	–	13251
2024 Q2	$113K	Buy	37,793 +1,143	+3%	+$3.45K	﹤0.01%	10933
2024 Q1	$126K	Buy	+36,650	New	+$108K	﹤0.01%	11054
2022 Q3	–	Sell	-4,327	Closed	-$22K	–	14287
2022 Q2	$22K	Buy	+4,327	New	+$26.3K	﹤0.01%	12349
2020 Q4	–	Sell	-1,274	Closed	-$12K	–	11840
2020 Q3	$12K	Buy	+1,274	New	+$33.1K	﹤0.01%	10409
2018 Q1	–	Sell	-11,663	Closed	-$528K	–	10334
2017 Q4	$528K	Buy	+11,663	New	+$784K	﹤0.01%	6538
2015 Q1	–	Sell	-49	Closed	-$12K	–	10036
2014 Q4	$12K	Buy	+49	New	+$12.1K	﹤0.01%	9508

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Susquehanna International Group's GRCE Position: Q3 2024 in Review

Susquehanna International Group sold out of Grace Therapeutics (GRCE) in Q3 2024, closing a stake of 37,793 shares — an estimated $113K sold.

Susquehanna International Group first reported a position in GRCE in Q4 2014 and held it in 6 quarters. The position peaked at $528K in Q4 2017. 12 funds tracked by Wall St. Rank hold GRCE as of Q3 2024.

Susquehanna International Group reported no remaining Grace Therapeutics position as of Q3 2024 after selling out during the quarter.
Susquehanna International Group sold 37,793 Grace Therapeutics shares in Q3 2024, an estimated $113K.
Susquehanna International Group first reported a position in Grace Therapeutics in Q4 2014 and held it in 6 quarters.
Susquehanna International Group's Grace Therapeutics position peaked at $528K in Q4 2017.
12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.